<!DOCTYPE html>
<html>
  <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-79742963-1', 'auto');
  ga('send', 'pageview');

</script>

  <!-- Begin Jekyll SEO tag v2.8.0 -->
<title>Less aggressive approach to neuroblastoma still effective | Ciência médica</title>
<meta name="generator" content="Jekyll v3.10.0" />
<meta property="og:title" content="Less aggressive approach to neuroblastoma still effective" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en_us" />
<meta name="description" content="In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report. In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275 received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of carboplatin, etoposide, cyclophosphamide and doxorubicin. “The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%,” Dr. David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology." />
<meta property="og:description" content="In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report. In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275 received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of carboplatin, etoposide, cyclophosphamide and doxorubicin. “The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%,” Dr. David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology." />
<link rel="canonical" href="https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html" />
<meta property="og:url" content="https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2007-06-05T20:52:00-03:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Less aggressive approach to neuroblastoma still effective" />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","author":{"@type":"Person","name":"Francisco H C Felix"},"dateModified":"2007-06-05T20:52:00-03:00","datePublished":"2007-06-05T20:52:00-03:00","description":"In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report. In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275 received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of carboplatin, etoposide, cyclophosphamide and doxorubicin. “The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%,” Dr. David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology.","headline":"Less aggressive approach to neuroblastoma still effective","mainEntityOfPage":{"@type":"WebPage","@id":"https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html"},"url":"https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html"}</script>
<!-- End Jekyll SEO tag -->

  <head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <!-- Begin Jekyll SEO tag v2.8.0 -->
<title>Less aggressive approach to neuroblastoma still effective | Ciência médica</title>
<meta name="generator" content="Jekyll v3.10.0" />
<meta property="og:title" content="Less aggressive approach to neuroblastoma still effective" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en_us" />
<meta name="description" content="In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report. In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275 received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of carboplatin, etoposide, cyclophosphamide and doxorubicin. “The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%,” Dr. David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology." />
<meta property="og:description" content="In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report. In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275 received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of carboplatin, etoposide, cyclophosphamide and doxorubicin. “The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%,” Dr. David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology." />
<link rel="canonical" href="https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html" />
<meta property="og:url" content="https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2007-06-05T20:52:00-03:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Less aggressive approach to neuroblastoma still effective" />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","author":{"@type":"Person","name":"Francisco H C Felix"},"dateModified":"2007-06-05T20:52:00-03:00","datePublished":"2007-06-05T20:52:00-03:00","description":"In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report. In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275 received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of carboplatin, etoposide, cyclophosphamide and doxorubicin. “The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%,” Dr. David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology.","headline":"Less aggressive approach to neuroblastoma still effective","mainEntityOfPage":{"@type":"WebPage","@id":"https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html"},"url":"https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html"}</script>
<!-- End Jekyll SEO tag -->


  <!--
 <link rel="alternate" hreflang="en-us" href="/ciencia-medica/2023/10/03/nobel-medicine-23.html" />
 <link rel="alternate" hreflang="en-us" href="/ciencia-medica/2022/10/03/nobel-medicine-22.html" />
 <link rel="alternate" hreflang="en-us" href="/ciencia-medica/2021/10/04/nobel-medicine-21.html" />
 <link rel="alternate" hreflang="en-us" href="/ciencia-medica/2020/10/05/nobel-medicine-20.html" />
 <link rel="alternate" hreflang="en-us" href="/ciencia-medica/2007/06/05/less-aggressive-approach-to.html" />
 <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/2023/10/03/nobel-medicina-2023.html" />
 <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/2022/10/03/nobel-medicina-22.html" />
 <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/2021/10/04/nobel-medicina-21.html" />
 <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/2020/10/05/nobel-medicina-20.html" />
 <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/2009/03/30/uso-de-propranolol-revoluciona.html" />
  
  <link rel="alternate" hreflang="" href="/ciencia-medica/feed.xml" />
  <link rel="alternate" hreflang="" href="/ciencia-medica/css/print.css" />
  <link rel="alternate" hreflang="" href="/ciencia-medica/css/tufte.css" />
  <link rel="alternate" hreflang="" href="/ciencia-medica/assets/css/style.css" />
  <link rel="alternate" hreflang="" href="/ciencia-medica/sitemap.xml" />
  <link rel="alternate" hreflang="" href="/ciencia-medica/robots.txt" />
  <link rel="alternate" hreflang="en" href="/ciencia-medica/cancer2/index.html" />
  <link rel="alternate" hreflang="en" href="/ciencia-medica/all-posts/index.html" />
  <link rel="alternate" hreflang="en" href="/ciencia-medica/vascular/index.html" />
  <link rel="alternate" hreflang="en" href="/ciencia-medica/markers/index.html" />
  <link rel="alternate" hreflang="en" href="/ciencia-medica/about/index.html" />
  <link rel="alternate" hreflang="en-us" href="/ciencia-medica/index.html" />
  <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/index-ptbr.html" />
  <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/todas-as-postagens/index.html" />
  <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/propranolol/index.html" />
  <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/sobre/index.html" />
  <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/cancer/index.html" />
  <link rel="alternate" hreflang="pt-br" href="/ciencia-medica/marcadores/index.html" />-->
 <!-- <link rel="alternate" type="application/rss+xml" title="" href="/ciencia-medica"> -->

  <title>Less aggressive approach to neuroblastoma still effective</title>
  <meta name="description" content="In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survivalrates comparable to or better than a mo...">

  <!-- Google Fonts loaded here depending on setting in _data/options.yml true loads font, blank does not-->
  
    <link href='https://fonts.googleapis.com/css?family=Lato:400,400italic' rel='stylesheet' type='text/css'>
  

  <!-- Load up MathJax script if needed ... specify in /_data/options.yml file-->
  
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
  

  <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/tufte.css">
  <!-- <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/print.css" media="print"> -->

  <link rel="canonical" href="https://fhcflx.github.io/ciencia-medica/2007/06/05/less-aggressive-approach-to.html">
  <link rel="icon"
        type="image/png"
        href="/assets/img/badge.png">

  <!-- <link rel="alternate" type="application/rss+xml" title="Ciência médica" href="https://fhcflx.github.io/ciencia-medica" /> -->

  <link rel="apple-touch-icon" sizes="180x180" href="/ciencia-medica/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/ciencia-medica/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/ciencia-medica/favicon-16x16.png">
  <link rel="manifest" href="/ciencia-medica/site.webmanifest">
  <link rel="mask-icon" href="/ciencia-medica/safari-pinned-tab.svg" color="#5bbad5">
  <link rel="shortcut icon" href="/ciencia-medica/favicon.ico">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/ciencia-medica/browserconfig.xml">
  <meta name="theme-color" content="#ffffff">

</head>

  <body>
    <!--- Hader and nav template site-wide -->
<header>
    <a class="site-title" href="/ciencia-medica/"></a>
    <nav class="group">
	<a href="/ciencia-medica/"><img class="badge" src="/ciencia-medica/assets/img/mybadge.png" alt="CH"></a>
        
	
		
		    
		      <a href="/ciencia-medica/index.html">Medical Science</a>
		    
	    
  	
        <!--<div class="trigger">
            
            
               
               <a class="page-link" href="/ciencia-medica/index.html">Medical Science</a>
               
            
            </div>-->
  </nav>
<div class="wrapper" style="text-align: right; line-height: 2em">
  
   <a href="/ciencia-medica/2023/10/03/nobel-medicine-23.html" class="en-us">en-us}</a>  <a href="/ciencia-medica/2022/10/03/nobel-medicine-22.html" class="en-us">en-us}</a>  <a href="/ciencia-medica/2021/10/04/nobel-medicine-21.html" class="en-us">en-us}</a>  <a href="/ciencia-medica/2020/10/05/nobel-medicine-20.html" class="en-us">en-us}</a>  <a href="/ciencia-medica/2007/06/05/less-aggressive-approach-to.html" class="en-us">en-us}</a>  <a href="/ciencia-medica/2023/10/03/nobel-medicina-2023.html" class="pt-br">pt-br}</a>  <a href="/ciencia-medica/2022/10/03/nobel-medicina-22.html" class="pt-br">pt-br}</a>  <a href="/ciencia-medica/2021/10/04/nobel-medicina-21.html" class="pt-br">pt-br}</a>  <a href="/ciencia-medica/2020/10/05/nobel-medicina-20.html" class="pt-br">pt-br}</a>  <a href="/ciencia-medica/2009/03/30/uso-de-propranolol-revoluciona.html" class="pt-br">pt-br}</a> 

  
   <a href="/ciencia-medica/feed.xml" class=""></a>  <a href="/ciencia-medica/css/print.css" class=""></a>  <a href="/ciencia-medica/css/tufte.css" class=""></a>  <a href="/ciencia-medica/assets/css/style.css" class=""></a>  <a href="/ciencia-medica/sitemap.xml" class=""></a>  <a href="/ciencia-medica/robots.txt" class=""></a>  <a href="/ciencia-medica/cancer2/index.html" class="en">en</a>  <a href="/ciencia-medica/all-posts/index.html" class="en">en</a>  <a href="/ciencia-medica/vascular/index.html" class="en">en</a>  <a href="/ciencia-medica/markers/index.html" class="en">en</a>  <a href="/ciencia-medica/about/index.html" class="en">en</a>  <a href="/ciencia-medica/index.html" class="en-us">en-us</a>  <a href="/ciencia-medica/index-ptbr.html" class="pt-br">pt-br</a>  <a href="/ciencia-medica/todas-as-postagens/index.html" class="pt-br">pt-br</a>  <a href="/ciencia-medica/propranolol/index.html" class="pt-br">pt-br</a>  <a href="/ciencia-medica/sobre/index.html" class="pt-br">pt-br</a>  <a href="/ciencia-medica/cancer/index.html" class="pt-br">pt-br</a>  <a href="/ciencia-medica/marcadores/index.html" class="pt-br">pt-br</a> 
</div>
</header>

    <article class="group">
      <h1>Less aggressive approach to neuroblastoma still effective</h1>
<p class="subtitle">

5
Junho
  
2007</p>





<ul class="tags">
  
    <li><a href="/ciencia-medica/marcadores#Cancer" class="tag">Cancer</a></li>
  
</ul>

<p>In infants and children with intermediate risk neuroblastoma, a reduced-intensity chemotherapy regimen yields survival
rates comparable to or better than a more aggressive regimen typically used in this patient population, researchers report.</p>

<p>In a study of 467 neuroblastoma patients, 192 received 4 cycles of chemotherapy in 64 days (the less intense arm) and 275
received 8 cycles in 168 days (the standard arm), following surgery. Chemotherapy consisted of 2 to 3 drug combinations of
carboplatin, etoposide, cyclophosphamide and doxorubicin.</p>

<p>“The bottom line is that with significantly less intense chemotherapy, we achieved 3-year overall survival of 96%,” Dr.
David L. Baker told the 43rd annual meeting of the American Society of Clinical Oncology.</p>


<article style="max-width: 90%;">
  <div id="disqus_thread"></div>
  <script>
    /**
     *  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
     *  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables
     */
    /*
    var disqus_config = function () {
        this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
        this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
    };
    */
      (function() {  // DON'T EDIT BELOW THIS LINE
          var d = document, s = d.createElement('script');
              s.src = 'https://pharmak-on.disqus.com/embed.js';

            s.setAttribute('data-timestamp', +new Date());
            (d.head || d.body).appendChild(s);
        })();
  </script>
  <noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript" rel="nofollow">comments powered by Disqus.</a></noscript>
</article>


    </article>
    <span class="print-footer">Less aggressive approach to neuroblastoma still effective - June 5, 2007 - fhcflx</span>
    <footer>
  <hr class="slender">
  <ul class="footer-links">
    <!-- <li><a href="mailto:fhcflx@outlook.com"><span class="icon-mail"></span></a></li> -->
    
      <li>
        <a href="https://www.twitter.com/neurodiversie"><span class="icon-twitter"></span></a>
      </li>
    
      <li>
        <a href="https://github.com/fhcflx/ciencia-medica"><span class="icon-github"></span></a>
      </li>
    
    <!-- <li><a href=https://travis-ci.org/fhcflx/ciencia-medica ><img alt='travis-ci build' src=https://img.shields.io/travis/fhcflx/ciencia-medica.svg?colorA=a00000&colorB=a00000></a></li> -->
  </ul>
<div class="credits">
<span>&copy; 2025 &nbsp;&nbsp;FHCFLX</span></br> <br>
<span>Este sítio foi criado com o <a href="https://github.com/clayh53/tufte-jekyll">tema Tufte para Ciência médica </a> no <a href="https://jekyllrb.com">Jekyll</a>.</span>
</div>
</footer>

  </body>
</html>
